法国代谢功能障碍相关脂肪性肝病相关肝硬化患者ICU住院后的患病率与预后:单中心前瞻性研究
在法国Pitié-Salpêtrière医院肝病ICU前瞻性纳入2019年1月至2021年9月住院的410例患者,分析315例。MASLD相关肝硬化总体患病率为10%,ALD为41%,MetALD为29.7%。三组1年无移植生存率无差异(53% vs 54% vs 54%,p=0.96),MASLD组1年发生肝性脑病的概率显著更高(73% vs 27%和21%,p<0.001)。
要点
- ICU住院肝硬化患者中MASLD相关肝硬化患病率为10%,MetALD为29.7%。
- MASLD组1年无移植生存率53%,与ALD组54%和MetALD组54%无显著差异(p=0.96)。
- MASLD组1年发生肝性脑病概率73%,显著高于ALD组的27%和MetALD组的21%(p<0.001)。
核心结论
- MASLD或MetALD导致了ICU中三分之一的肝硬化病因。
- MASLD相关肝硬化与ALD相关肝硬化同样严重。
- 应尽快讨论肝移植。
研究设计与样本
- 前瞻性单中心研究,纳入2019年1月至2021年9月在Pitié-Salpêtrière医院肝病ICU住院的患者。
- 共410例患者住院,315例纳入分析:MASLD组39例、ALD组160例、MetALD组116例。
主要发现
- 总体患病率:MASLD为10%,ALD为41%,MetALD为29.7%。
- MASLD组患者年龄显著更大(65岁 vs 57岁和59岁,p<0.001)。
- MASLD组Child-Pugh评分显著更低(8 vs 11 vs 10,p<0.001),MELD评分显著更低(17 vs 22 vs 21,p<0.001)。
- 1年无移植生存率组间无差异(53% vs 54% vs 54%,p=0.96)。
- 所有组心血管死亡率均<5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related cirrhosis has been increasing these last decades. There are no data regarding the prevalence of MASLD-related cirrhosis in intensive care unit (ICU). METHODS: Prospective single-centre study in a cohort of patients hospitalized in the ICU of Hepatology La Pitié-Salpêtrière Hospital between January 2019 and September 2021. We analysed three groups of patients: MASLD-cirrhosis (alcohol ≤210 g for men and 140 g weekly for women), ALD (alcohol-related liver disease, alcohol>140 g weekly for women or >210 g for men)-cirrhosis alone and MetALD (metabolic and alcohol-related liver disease)-cirrhosis. Endpoints were 1-year transplant-free survival (TFS), further acute decompensation (AD) and re-admission. RESULTS: A total of 410 patients were hospitalized, and 315 analysed: 39 in MASLD, 160 in ALD and 116 in MetALD groups. The global prevalence was 10% for MASLD, 41% ALD and 29.7% for MetALD. Patients in the MASLD group were significantly older (65 vs. 57 and 59 years, p < 0.001), and had lower Child-Pugh (8 vs. 11 vs. 10, p < 0.001) and MELD score (17 vs. 22 vs. 21, p < 0.001). The 1-year TFS was not different between groups (53% vs. 54% vs. 54%, p = 0.96). Cardiovascular mortality was <5% in all groups. The 1-year probability of developing hepatic encephalopathy was significantly higher in the MASLD group (73% vs. 27% and 21%, p < 0.001). There was no difference regarding the development of other complications between groups. CONCLUSION: MASLD or MetALD was responsible for 1/3 of the causes of cirrhosis in the ICU. MASLD-related cirrhosis is as severe as ALD-related cirrhosis. Liver transplantation should be rapidly discussed.
引用
- Sultanik P, Lherault G, Bouzbib C, et al. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study. Aliment Pharmacol Ther. 2024. PMID: 39034817. doi:10.1111/apt.18165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。